Expertise in
1
conditions

Marie-eve Garcia

Ap Hm
Marseille, FR 
Expertise in
1
conditions
Ap Hm
Marseille, FR 

Overview

Marie-eve Garcia practices practicing medicine in Marseille, France.

Garcia is highly rated in 1 condition, according to our data. Their clinical expertise encompasses COVID-19, Adrenocortical Carcinoma, Melanoma, and Adrenal Cancer.

They are actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 2 clinical trials.

Locations

AP HM
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
View 1 Less Clinical Trial

11 Total Publications

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.
Journal: Communications medicine
Published: February 23, 2026

Frequently Asked Questions about Marie-eve Garcia

Is Marie-eve Garcia a top-rated expert for COVID-19?

MediFind is an objective health platform that identifies experts based on real-world data. Marie-eve Garcia is classified as an Advanced expert for COVID-19, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marie-eve Garcia participate in research or clinical trials?

Yes. Marie-eve Garcia has published 11 articles and abstracts on conditions like COVID-19. You can view a list of Marie-eve Garcia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Garcia's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile